What question did this study set out to answer?

To evaluate the impact of pre-transplant disease characteristics and therapy on post-transplant outcomes.

December 8, 2025Blood

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study reveals therapy and TP53 mutations affect post-transplant outcomes in higher-risk myelodysplastic syndromes.

To evaluate the impact of pre-transplant disease characteristics and therapy on post-transplant outcomes.
Single center retrospective study
Identified patients with higher-risk myelodysplastic syndromes
Evaluated responses using IWG 2023 criteria
Analyzed time-to-event endpoints with Fine-Gray and Cox proportional hazards regression
2045 patients identified, 427 underwent SCT
5-year overall survival was 40% for transplanted patients
Post-transplant cyclophosphamide was administered in 42% of patients
TP53 mutations associated with significantly worse survival outcomes

Garcia‐Manero et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark